Eiken Chemical (4549) · InitiativeAdvanced
Establishment of EIKEN MEDICAL AMERICA INC.
First written in FY2025. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Establishment of a Sales Base and Sales Activities Targeting North AmericaA theme 12 companies write about · 0 as a headwind · 12 as a tailwind
The whole theme swung hardest in 2020: 1 of 6 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「The Company will also begin selling immunoserum reagents through its U.S. subsidiary, and will further expand its earnings base by combining value-added technologies for FIT products to create new markets and demand.」
The U.S. subsidiary, which had been reported as not having commenced operations since its establishment in November 2023, progressed to the launch of immunoserum reagent sales. The combination of value-added technologies for FIT was also presented as a means of creating new markets and demand. - FY2025First statedAnnual report
「EIKEN MEDICAL AMERICA INC. has not commenced operations.」
The U.S. sales subsidiary established in November 2023 was listed as a consolidated subsidiary, but had not commenced operations as of the end of the fiscal year.